Program Description
Epilepsy continues to pose significant challenges to health care practitioners and represents one of the more difficult neurological disorders to effectively treat. However, areas such as bioequivalence, generic substitution, and neuroprotection are constantly evolving as areas for helping to improve this debilitating disorder. Dr. Welty is here to speak on epilepsy from the pharmacist standpoint, and address ways in which the disorder can be more effectively managed.
Hosted by
Larry Kaskel, MD
Learning Objectives
- Describe the adverse events that may follow generic substitution of AEDs, and the role of the pharmacist in encouraging reporting of these adverse events to the FDA.
- Discuss the emerging clinical data on the benefits of including pharmacists as part of collaborative drug therapy management in epilepsy clinics.
Target Audience
The target audience for this educational activity is physicians and pharmacists.
Faculty/Disclosures
Faculty:
Timothy E Welty MA PharmD FCCP BCPS
Professor and Chair
Department of Pharmacy Practice
School of Pharmacy
University of Kansas
Kansas City, KS
Dr. Welty has received consulting fees from UCB Pharma and GlaxoSmithKline. He serves on the Access to Continuity of Supply for the American Epilepsy Society and is part of the core working group that is designing a trial on generic substitution for a NIH grant; he currently has a planning grant from NIH to work on this project.
Clinical Editor:
Christopher J. Drury
Mr. Drury has nothing to disclose.
Accreditation
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Pri-Med Institute designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Pri-Med Institute is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Pri-Med Institute designates this continuing education activity for .5 contact hours of continuing pharmacy education. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Provider
This activity is co-sponsored by Pri-Med Institute and the American Epilepsy Society.
Pri-Med is a brand within M|C Communications, LLC. Offered through the Pri-Med brand are both educational solutions for physicians and allied health professionals and non-CME product information sharing and exhibit opportunities for industry. Pri-Med's educational solutions are fully firewalled from the non-CME offerings and are developed compliantly and in accordance with accrediting organization requirements and standards, including the ACCME. Pri-Med's CME provides health care practitioners with access to evidence-based education through innovative learning formats designed to meet their individual needs. Pri-Med's offerings include 120+ live meetings and conventions across the U.S., in the UK, and Germany; 300+ online CME activities and web-based tools and resources on www.pri-med.com, one of the top ten CME websites available to physicians; and 60+ print publications read by 200,000+ clinicians.
The American Epilepsy Society (AES) is one of 98 chapters of the International League Against Epilepsy (ILAE). The AES promotes research and education for professionals dedicated to the prevention, treatment and cure of epilepsy.
Commercial Support
Pri-Med Institute gratefully acknowledges the educational grant provided by GlaxoSmithKline and UCB, Inc.
Disclosure of Unlabeled Use
This presentation may contain mention of unapproved or investigational therapeutic agents. Pri-Med Institute and this activity's commercial grantors do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This discussion does not represent an official position of Pri-Med or the American Epilepsy Society, but is presented as a public service to the medical community to inform it of the current issues surrounding the use of generic medications for the treatment of epilepsy.
Instruction for Participation
To earn continuing education credit, simply listen to the podcast program. Learners must then complete a posttest and evaluation and receive a passing score of 70% or more on the posttest. Upon submission of the evaluation, learners will have the option of printing a certificate for their records.